Cargando…

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial

The PACIFIC trial showed a survival benefit with durvalumab through five years in stage III unresectable non-small cell lung cancer (NSCLC). However, optimal use of imaging to detect disease progression remains unclearly defined for this population. An expert working group convened to consider avail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Jenny J., Banerji, Shantanu, Blais, Normand, Brade, Anthony, Clelland, Cathy, Schellenberg, Devin, Snow, Stephanie, Wheatley-Price, Paul, Yuan, Ren, Melosky, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137068/ https://www.ncbi.nlm.nih.gov/pubmed/37185402 http://dx.doi.org/10.3390/curroncol30040289

Ejemplares similares

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023)

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
por: Ionescu, Diana N., et al.
Publicado: (2022)

A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
por: Brade, Anthony, et al.
Publicado: (2021)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC
por: Zhao, Qianqian, et al.
Publicado: (2019)

Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
por: Shang, Shijie, et al.
Publicado: (2022)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †
por: Bebb, D. Gwyn, et al.
Publicado: (2021)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china
por: Jiang, Xiaotong, et al.
Publicado: (2022)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China
por: Li, Wei, et al.
Publicado: (2023)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
por: Gauvin, Camille, et al.
Publicado: (2021)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
por: Dunlop, Will, et al.
Publicado: (2021)

Canadian supportive care recommendations for the management of anemia in patients with cancer
por: Mikhael, J., et al.
Publicado: (2007)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia
por: Koh, Natalie, et al.
Publicado: (2021)

Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial
por: Banga, Sandeep, et al.
Publicado: (2019)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Melosky, Barbara, et al.
Publicado: (2021)

COPD Guidelines in the Asia-Pacific Regions: Similarities and Differences
por: Cheng, Shih-Lung, et al.
Publicado: (2021)

Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center “Blue Sky Radiomics” study on stage III unresectable NSCLC
por: Cabini, Raffaella Fiamma, et al.
Publicado: (2022)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gt8psl4c9laqngaubie968nhfl